Prothya Biosolutions
CompanyNetherlands
Prothya Biosolutions develops one asset, in phase 3, no development reported (Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified in chronic inflammatory demyelinating polyneuropathy). Mostly plasma or blood product; based in Netherlands.
- 1
- Asset
- Furthest stage
- Phase 3, no development reported
- 2
- Trials
- 25
- Signals
Pipeline
1Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified
Replaces deficient immunoglobulin G to provide passive immunity against infections.
Phase 3, no development reported, Plasma or blood product, chronic inflammatory demyelinating polyneuropathy, dermatomyositis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials6
- People1
- Signals20
- Similar companies6